{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:58:39Z","timestamp":1772729919892,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and objective<\/jats:title>\n            <jats:p>Atrial fibrillation (AF) is the most common sustained arrhythmia, with high recurrence rates following radiofrequency catheter ablation (RFCA). Identifying predictors of atrial tachyarrhythmia (Ata) recurrence is crucial for risk stratification and personalized management. The HARMS<jats:sub>2<\/jats:sub>-AF score, a novel lifestyle-based risk score comprising hypertension, age, BMI\u2009\u2265\u200930\u00a0kg\/m\u00b2, male sex, sleep apnea, smoking, and alcohol consumption, has emerged as a potential predictor for Ata recurrence. This study aimed to evaluate the association between the HARMS<jats:sub>2<\/jats:sub>-AF score and Ata recurrence after RFCA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of 152 patients who underwent RFCA at Kunshan Hospital of Traditional Chinese Medicine between January 2021 and December 2022. Ata recurrence was defined as documented episodes of atrial flutter, atrial tachycardia, or AF lasting more than 30\u00a0s on ECG or 24-hour Holter monitorin during follow-up. Based on Ata recurrence, patients were classified into recurrence (<jats:italic>n<\/jats:italic>\u2009=\u200944) and non-recurrence (<jats:italic>n<\/jats:italic>\u2009=\u2009108) groups. Clinical characteristics, CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score, and HARMS<jats:sub>2<\/jats:sub>-AF score were compared between the two groups. Spearman\u2019s rank correlation analysis was performed to assess the relationships between the HARMS<jats:sub>2<\/jats:sub>-AF score, CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score, left atrial diameter (LAD), and Ata recurrence. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of Ata recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients in the recurrence group exhibited a higher prevalence of persistent AF (<jats:italic>P<\/jats:italic>\u2009=\u20090.002), larger LAD (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and higher CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and HARMS<jats:sub>2<\/jats:sub>-AF scores (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared to the non-recurrence group. Spearman\u2019s rank correlation analysis revealed significant positive correlations between the HARMS<jats:sub>2<\/jats:sub>-AF score (<jats:italic>r<\/jats:italic>\u2009=\u20090.626, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score (<jats:italic>r<\/jats:italic>\u2009=\u20090.452, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and LAD (<jats:italic>r<\/jats:italic>\u2009=\u20090.405, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) with Ata recurrence. Multivariate analysis revealed that LAD (OR\u2009=\u20091.280, 95% CI\u2009=\u20091.118\u20131.464), CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc (OR\u2009=\u20093.773, 95% CI\u2009=\u20091.897\u20137.503), and HARMS<jats:sub>2<\/jats:sub>-AF (OR\u2009=\u20093.106, 95% CI\u2009=\u20091.866\u20135.168) were independent predictors for Ata recurrence after RFCA. The HARMS<jats:sub>2<\/jats:sub>-AF score demonstrated high sensitivity (93.2%) and specificity (79.6%) for predicting Ata recurrence. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.895 for HARMS<jats:sub>2<\/jats:sub>-AF, 0.777 for CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc, and 0.757 for LAD, with HARMS<jats:sub>2<\/jats:sub>-AF showing superior predictive accuracy (<jats:italic>P<\/jats:italic>\u2009=\u20090.008 vs. CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc, <jats:italic>P<\/jats:italic>\u2009=\u20090.007 vs. LAD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The HARMS<jats:sub>2<\/jats:sub>-AF score is significantly associated with Ata recurrence after RFCA and provides a valuable tool for risk prediction. A cut-off value of 7.5 for the HARMS<jats:sub>2<\/jats:sub>-AF score demonstrates high sensitivity and specificity for predicting Ata recurrence, offering superior prognostic value compared to traditional risk factors. Additionally, Spearman\u2019s rank correlation analysis confirms the strong relationship between lifestyle-related factors (as captured by the HARMS<jats:sub>2<\/jats:sub>-AF score) and Ata recurrence, further supporting the clinical relevance of this score.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12872-025-05110-y","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:53:25Z","timestamp":1756367605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of HARMS2-AF score with atrial tachyarrhythmia recurrence after radiofrequency catheter ablation: a retrospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaochen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"11","key":"5110_CR1","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1055\/a-1807-0336","volume":"122","author":"TF Chao","year":"2022","unstructured":"Chao TF, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip G, Chen SA. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<\u20093 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost. 2022;122(11):1899\u2013910.","journal-title":"Thromb Haemost"},{"key":"5110_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.amjcard.2021.08.042","volume":"160","author":"EL O\u2019Keefe","year":"2021","unstructured":"O\u2019Keefe EL, Sturgess JE, O\u2019Keefe JH, Gupta S, Lavie CJ. Prevention and treatment of atrial fibrillation via risk factor modification. Am J Cardiol. 2021;160:46\u201352.","journal-title":"Am J Cardiol"},{"key":"5110_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1393208","volume":"11","author":"C Fei","year":"2024","unstructured":"Fei C, Zhao C, Ma Y, Liu Y, Chen R, Zhang H. Factors influencing early recurrence of atrial fibrillation among elderly patients following radiofrequency catheter ablation and the impact of different antiarrhythmic regimens. Front Med. 2024;11: 1393208.","journal-title":"Front Med"},{"issue":"16","key":"5110_CR4","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","volume":"141","author":"MK Chung","year":"2020","unstructured":"Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750-750772.","journal-title":"Circulation"},{"issue":"15","key":"5110_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/2047487318796625","volume":"25","author":"M Halle","year":"2018","unstructured":"Halle M, Haykowsky M. Atrial fibrillation: a preventable lifestyle disease. Eur J Prev Cardiol. 2018;25(15):1642\u20135.","journal-title":"Eur J Prev Cardiol"},{"issue":"36","key":"5110_CR6","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/eurheartj\/ehad423","volume":"44","author":"GM Marcus","year":"2023","unstructured":"Marcus GM. Translating HARMS2-AF into benefits for our atrial fibrillation patients and the general public: challenges and opportunities. Eur Heart J. 2023;44(36):3453\u20135.","journal-title":"Eur Heart J"},{"issue":"1","key":"5110_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1\u20131156.","journal-title":"Circulation"},{"issue":"7","key":"5110_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/eurheartj\/ehad572","volume":"45","author":"JG Andrade","year":"2024","unstructured":"Andrade JG, Deyell MW, Khairy P, et al. Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: the CIRCA-DOSE trial. Eur Heart J. 2024;45(7):510\u20138.","journal-title":"Eur Heart J"},{"issue":"14","key":"5110_CR9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/eurjpc\/zwae111","volume":"31","author":"T Ko","year":"2024","unstructured":"Ko T, Suzuki Y, Kaneko H, et al. Applying the HARMS2-atrial fibrillation risk score for Japanese population: an analysis of a nationwide epidemiological dataset. Eur J Prev Cardiol. 2024;31(14):1738\u201340.","journal-title":"Eur J Prev Cardiol"},{"issue":"36","key":"5110_CR10","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/eurheartj\/ehad375","volume":"44","author":"L Segan","year":"2023","unstructured":"Segan L, Canovas R, Nanayakkara S, et al. New-onset atrial fibrillation prediction: the HARMS2-AF risk score. Eur Heart J. 2023;44(36):3443\u201352.","journal-title":"Eur Heart J"},{"key":"5110_CR11","unstructured":"Rodr\u00edguez-Reyes H, Asensio-Lafuente E, Coss\u00edo-Aranda JE et al. [Lifestyle modification and risk factor control in the prevention and treatment of atrial fibrillation]. Arch Cardiol Mex. 2024."},{"issue":"5","key":"5110_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/heartjnl-2019-315327","volume":"106","author":"ME Middeldorp","year":"2020","unstructured":"Middeldorp ME, Ariyaratnam J, Lau D, Sanders P. Lifestyle modifications for treatment of atrial fibrillation. Heart. 2020;106(5):325\u201332.","journal-title":"Heart"},{"issue":"4","key":"5110_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/jce.15376","volume":"33","author":"K Kumagai","year":"2022","unstructured":"Kumagai K. The electrophysiological characteristics of the initiation of atrial fibrillation from the pulmonary veins. J Cardiovasc Electrophysiol. 2022;33(4):638\u201340.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"5110_CR14","first-page":"102611","volume":"72","author":"C Tran","year":"2024","unstructured":"Tran C, Yeap BB, Ball J, et al. Testosterone and the risk of incident atrial fibrillation in older men: further analysis of the ASPREE study. EClinMed. 2024;72:102611.","journal-title":"EClinMed"},{"issue":"4","key":"5110_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104459","volume":"65","author":"G Wren","year":"2022","unstructured":"Wren G, Davies W. Sex-linked genetic mechanisms and atrial fibrillation risk. Eur J Med Genet. 2022;65(4): 104459.","journal-title":"Eur J Med Genet"},{"issue":"1","key":"5110_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccep.2020.10.010","volume":"13","author":"J Zhang","year":"2021","unstructured":"Zhang J, Johnsen SP, Guo Y, Lip G. Epidemiology of atrial fibrillation: geographic\/ecological risk factors, age, sex, genetics. Card Electrophysiol Clin. 2021;13(1):1\u201323.","journal-title":"Card Electrophysiol Clin"},{"issue":"1","key":"5110_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40001-024-01952-y","volume":"29","author":"W Huang","year":"2024","unstructured":"Huang W, Sun H, Xiong S, Luo Y, Tang Y, Zhang Z, Liu H. Sex-related differences in left atrial substrate among patients with atrial fibrillation: evidence from high-density voltage mapping. Eur J Med Res. 2024;29(1):354.","journal-title":"Eur J Med Res"},{"issue":"3","key":"5110_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.acvd.2018.10.006","volume":"112","author":"H Deng","year":"2019","unstructured":"Deng H, Shantsila A, Guo P, et al. Sex-related risks of recurrence of atrial fibrillation after ablation: insights from the Guangzhou atrial fibrillation ablation registry. Arch Cardiovasc Dis. 2019;112(3):171\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"6","key":"5110_CR19","first-page":"1024","volume":"6","author":"H Beck","year":"2014","unstructured":"Beck H, Curtis AB. Sex differences in outcomes of ablation of atrial fibrillation. J Atr Fibrillation. 2014;6(6):1024.","journal-title":"J Atr Fibrillation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05110-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05110-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05110-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:45:36Z","timestamp":1757447136000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05110-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05110-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Kunshan Hospital of Traditional Chinese Medicine. Since this is a retrospective observational study and no new treatment interventions were performed on patients, after review by the ethics committee, the requirement for obtaining informed consent from patients was waived. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"636"}}